Open AccessEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Author(s) -
Thomas Powles,
Jonathan E. Rosenberg,
Guru Sonpavde,
Yohann Loriot,
Ignacio Durán,
JaeLyun Lee,
Nobuaki Matsubara,
Christof Vulsteke,
Daniel Castellano,
Chunzhang Wu,
Mary S. Campbell,
Maria Matsangou,
Daniel P. Petrylak
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2035807
Subject(s) - medicine , hazard ratio , chemotherapy , oncology , docetaxel , surgery , confidence interval
Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom